Attovia Therapeutics Inc.
Organization details
- Legal name
- Attovia Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Carlos
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ATTO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002058707
- EIN
- 92-1510574
Board of directors
-
Aaron Royston · DirectorSince 2026
-
Angie You · DirectorSince 2026
-
Colin Walsh · DirectorSince 2026
-
James N. Topper · DirectorSince 2026
-
John W. Smither · DirectorSince 2026
-
Mitchell Gold · DirectorSince 2026
-
Tao Fu · Director · President and CEOSince 2026
Chief executives
Board connections
4 of this board's directors also sit on 6 other boards. 6 are in the same sector.
-
NewAmsterdam Pharma Company N.V. Same sectorvia James N. Topper and John W. Smither
-
Achieve Life Sciences Inc. Same sectorvia Aaron Royston
-
AnaptysBio Inc. Same sectorvia James N. Topper
-
Genelux Corporation Same sectorvia John W. Smither
-
Oric Pharmaceuticals Inc. Same sectorvia Angie You
-
Phathom Pharmaceuticals Inc. Same sectorvia James N. Topper
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $52,369,979
- 9 purchases by 6 insiders
- Sold, last 12 months
- $4,503,315
- 46 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | FHMLS XI, L.P. 10% owner | Derivative conversion | +1,749,192 | — | — |
| Aug 6, 2026 | Jeremy Green 10% owner | Derivative conversion | +782,854 | — | — |
| Aug 6, 2026 | Sanofi 10% owner | Derivative conversion | +782,855 | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Derivative conversion | +2,311,870 | — | — |
| Aug 6, 2026 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Derivative conversion | +1,957,138 | — | — |
| Aug 6, 2026 | FHMLS XI, L.P. 10% owner | Derivative conversion | +1,590,175 | — | — |
| Aug 6, 2026 | Jeremy Green 10% owner | Open-market purchase | +200,000 | $17.00 | $3,400,000 |
| Aug 6, 2026 | Sanofi 10% owner | Open-market purchase | +300,000 | $17.00 | $5,100,000 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Derivative conversion | +821,998 | — | — |
| Aug 6, 2026 | FHMLS XI, L.P. 10% owner | Derivative conversion | +1,189,940 | — | — |
| Aug 6, 2026 | Jeremy Green 10% owner | Open-market purchase | +400,000 | $17.00 | $6,800,000 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Derivative conversion | +665,147 | — | — |
| Aug 6, 2026 | FHMLS XI, L.P. 10% owner | Derivative conversion | +961,322 | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Open-market purchase | +382,352 | $17.00 | $6,499,984 |
| Aug 6, 2026 | FHMLS XI, L.P. 10% owner | Open-market purchase | +588,235 | $17.00 | $9,999,995 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Attovia Therapeutics Inc.
Who is the CEO of Attovia Therapeutics Inc.?
Tao Fu has been Attovia Therapeutics Inc.'s President and CEO since August 2026.
How many directors are on Attovia Therapeutics Inc.'s board?
Attovia Therapeutics Inc.'s board has 7 directors: Aaron Royston, Angie You, Colin Walsh, James N. Topper, John W. Smither, Mitchell Gold and Tao Fu.
Are Attovia Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Attovia Therapeutics Inc. insiders bought $52.4 million of shares in 9 purchases and sold $4.5 million of shares in 46 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="attovia-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.